📰 ReutersReutersCodex · 实盘不做把握 8/10
北京时间·🕒 发布 19:03:53时区推断·⟳ 抓取 19:05:43·⚡ 决策 07-28 20:53:19 +1h47m·91.0 天前
GSK将在英国三年投资4亿英镑建设剑桥研发中心
这是一项多年期研发与场地搬迁投资，主要属于战略与运营布局，不直接形成短周期收入、利润或订单增量。
📄 原文Reuters↗ 原文
British drugmaker GSK (GSK.L) said on Tuesday that it will invest £400 million ($531.12 million) over 3 years in the c…
不做 GSK（GSK.GB）
多年期研发中心与设施调整属于战略投入，金额相对现有研发基数不大，无法形成短周期可交易的收入或利润催化。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-28 · 扩散 medium · price-in 风险 medium ↗
关键理由
- 这是一项多年期研发与场地搬迁投资，主要属于战略与运营布局，不直接形成短周期收入、利润或订单增量。
- 4亿英镑分三年投入，相比GSK每年超过60亿英镑的全球研发投入、英国每年超过15亿英镑研发投入，量级不足以推动主标的短线重定价。
- 同文提到AstraZeneca此前也宣布英国投资，说明该类英国药企本土研发投入更像行业与政策背景延续，而非单公司超预期催化。
主要风险
- 若后续披露该研发中心绑定重大管线突破、税收补贴或监管定价让步，需按新事件重新评估。
原文全文
展开原文 · 1,404 字
British drugmaker GSK (GSK.L) said on Tuesday that it will invest £400 million ($531.12 million) over 3 years in the country, including a new R&D center in Cambridge as part of its plans to develop medicines faster under new CEO Luke Miels.
GSK's investments comes a few months after an agreement between the U.S. and UK, aimed at increasing medicine prices in Britain in line with the U.S. President Donald Trump's new U.S. pricing policies was finalised in April.
Rival AstraZeneca (AZN.L) had announced a £300 million($398.34 million) investment in Britain earlier this year, reversing its decision to pause large-scale projects.
GSK said that the new 300,000 square foot site in Cambridge, home to one of Britain's leading life sciences hubs, will support research in its focus therapeutics areas including for new cancer and respiratory drugs.
"This investment will accelerate our R&D and help us deliver new, competitive products," said CEO Luke Miels.
As part of the investment, GSK said it will vacate its Stevenage R&D site by 2029 and also upgrade its facility in Ware, relocating some staff there.
The new Cambridge centre will accommodate more than 1,000 scientists, and its London global headquarters remains unchanged.
GSK invests over £6 billion ($7.97 billion) in R&D annually, with more than £1.5 billion ($1.99 billion) spent in the UK.
($1 = 0.7531 pounds)
GSK's investments comes a few months after an agreement between the U.S. and UK, aimed at increasing medicine prices in Britain in line with the U.S. President Donald Trump's new U.S. pricing policies was finalised in April.
Rival AstraZeneca (AZN.L) had announced a £300 million($398.34 million) investment in Britain earlier this year, reversing its decision to pause large-scale projects.
GSK said that the new 300,000 square foot site in Cambridge, home to one of Britain's leading life sciences hubs, will support research in its focus therapeutics areas including for new cancer and respiratory drugs.
"This investment will accelerate our R&D and help us deliver new, competitive products," said CEO Luke Miels.
As part of the investment, GSK said it will vacate its Stevenage R&D site by 2029 and also upgrade its facility in Ware, relocating some staff there.
The new Cambridge centre will accommodate more than 1,000 scientists, and its London global headquarters remains unchanged.
GSK invests over £6 billion ($7.97 billion) in R&D annually, with more than £1.5 billion ($1.99 billion) spent in the UK.
($1 = 0.7531 pounds)
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。